GRØNVOLD MAJA SOMMERFELT,SØRENSEN BIRGER,LAWITZ KAROLINA,LANGE EINAR TØNNES
申请号：
NZ61182012
公开号：
NZ611820A
申请日:
2012.01.06
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
Disclosed is an isolated multimeric peptide comprising two or more monomeric peptides, each monomeric peptide independently consisting of not more than 60 amino acids with the following structure: X1-X2-X3-X4-X5-X6 (formula I), wherein: X1, X3 and optional moiety X5 each independently define a linear sequence of any 1, 2, 3, 4, or 5 amino acids independently selected from glycine, arginine, norleucine, aspartic acid, glutamic acid, glutamine, serine, lysine, tryptophan, cysteine, ornithine, diaminopropionic acid or a derivative thereof； X2, X4 and optional moiety X6 each independently define a linear sequence of 5-17 amino acids, each having 50% or more sequence identity to a specific natural antigen； the monomeric peptides being covalently joined by one or more intermolecular bonds； wherein in one of the monomeric peptides the sequence of X2 is selected from IEEEG (SEQ ID NO: 72) and GIEEE (SEQ ID NO: 76), X3 is G or GG, and X4 is RDRDR (SEQ ID NO: 95), with the proviso that this peptide is not GKGGIEEEGGRDRDRGGEQDRDR (SEQ ID NO: 122). Also disclosed is a method for evaluating the efficacy of a vaccine comprising stimulating a sample of peripheral blood mononuclear cells (PBMCs) obtained from a patient treated with the vaccine with the multimeric peptide as defined above.
